Table 4.
Insulin glargine | NPH insulin | |
---|---|---|
(n = 107) | (n = 54) | |
Any hypoglycaemiaa, n (%) | 99 (92.5) | 51 (94.4) |
Events per patient yearb, mean ± SD | 68.6 ± 69.4 | 84.6 ± 79.3 |
Asymptomatic hypoglycaemiaa, n (%) | 93 (86.9) | 47 (87.0) |
Events per patient yearb, mean ± SD | 44.4 ± 48.7 | 52.3 ± 65.3 |
Symptomatic hypoglycaemiaa, n (%) | 74 (69.2) | 41 (75.9) |
Events per patient yearb, mean ± SD | 24.3 ± 45.8 | 32.3 ± 43.2 |
Severe symptomatic hypoglycaemiaa, n (%) | 1 (0.9) | 1 (1.9) |
Events per patient yearb, mean ± SD | 0.02 ± 0.20 | 0.04 ± 0.31 |
Nocturnal hypoglycaemiaa, n (%) | 83 (77.6) | 42 (77.8) |
Events per patient yearb, mean ± SD | 13.0 ± 15.0 | 14.2 ± 16.9 |
Nocturnal symptomatic hypoglycaemiaa, n (%) | 40 (37.4) | 25 (46.3) |
Events per patient yearb, mean ± SD | 3.6 ± 7.3 | 4.5 ± 7.4 |
aCalculated as the total number of patients with at least one episode from the first dose of treatment up to 24 h after the last dose of treatment divided by the total number of patients in the safety population
bCalculated as the total number of episodes divided by the total duration from the first dose to ≤24 h after the last dose of study medication (in years)